In patients with high-risk HER2-positive breast cancer after surgery or adjuvant therapy, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared with trastuzumab alone, according to final trial results KATHERINE phase III clinical trial conducted by scientists from the University of Pittsburgh and UPMC […]
In a recent study published in the journal researchers are analyzing tumor architecture, cell composition, and the microenvironment in patients with triple-negative breast cancer (TNBC) using spatial transcriptomics and histomorphological analysis. A total of nine TNBC spatial archetypes were identified and associated with disease outcomes and actionable characteristics, as well as a tertiary lymphatic gene […]